ABSTRACT
Objectives The present COVID-19 pandemic (C19P) is challenging our socities all over the world. In this work, based on massive health information daily updated, the C19P daily death numbers at a global level, are modelled, analyzed and forecasted.
Methods Two empirical models are proposed to explain daily death (DD) records: a) self-similar (SS) recurrences of the global responses, and b) geometric averaging of two independent SS models for global DD records.
Findings The detected self-similar recurrences in the global response suggest three global “self-similar waves” that support multi-month forecasts of the DD numbers. However, there are upper and lower-limit SS forecast DD scenarios that were jointly integrated with a geometrical average (GA) model, that support the existence of a moderated “third wave”, with a decaying stage for the next months (July-September 2020). It appears that the “third world” (South America [SAM]+Asia [ASI] +Africa [AFR]), is the actual “big player”, (following China, and Europe [EUR]+North America [NAM]) with its biggest contribution to a global “third wave” (W3) of C19P.
Conclusion The empirical global modeling of the C19P has suggested us a possible moderated W3 scenario, with contributions mainly coming from the third world people. This moderated W3 scenario, after to be calibrated with the last weeks, has provided to stakeholders of significant data and criteria to define, sustain and support plans for the next months, based on data and self-similarities. These scenarios provide a well-based perspective on non-linear dynamics of C19P, that will complement the standard health and economic models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was employed in this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
all relevant ethical guidelines have been followed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Information used can be accessed in an open site
